Moderna, Inc. (NASDAQ:MRNA) | Finanzwire

Basculer en Français

10514	Companies
221717	Keywords
150876	Articles
117252	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 08/01/2025 at 13:00, 10 months 3 days ago

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates
Moderna reports Q2 revenue of $0.1B, net loss of $(0.8)B, updates 2025 revenue to $1.5-$2.2B due to shipment timing, improves operating expenses by $400M, reiterates $6B year-end cash balance. FDA approvals for flu vaccine

Revenue Moderna Q2 2025 FDA Approvals
BRIEF

published on 08/01/2025 at 12:05, 10 months 3 days ago

UK Court Confirms Validity of Moderna's EP'949 Patent

Patent MRNA Technology Moderna Pfizer/BioNTech UK Court
PRESS RELEASE

published on 08/01/2025 at 12:00, 10 months 3 days ago

UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech
Moderna's EP'949 patent validity upheld by UK Court of Appeal in Pfizer/BioNTech case. Recent legal developments in Europe further strengthen Moderna's intellectual property portfolio

MRNA Technology Moderna Pfizer/BioNTech EP'949 Patent UK Court Of Appeal
BRIEF

published on 07/30/2025 at 22:10, 10 months 4 days ago

Moderna Gains European Approval for New COVID-19 Vaccine

COVID-19 Vaccine European Commission Moderna SARS-CoV-2 SPIKEVAX®
PRESS RELEASE

published on 07/30/2025 at 22:05, 10 months 4 days ago

Moderna Receives European Commission Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1
Moderna receives marketing authorization from the European Commission for updated COVID-19 vaccine Spikevax® targeting SARS-CoV-2 variant LP.8.1

COVID-19 Vaccine European Commission Moderna Spikevax LP.8.1
BRIEF

published on 07/28/2025 at 13:05, 10 months 7 days ago

Moderna to Present mRNA Therapeutics Data at ESMO Congress 2025

MRNA Therapeutics Moderna Melanoma Bladder Cancer ESMO Congress 2025
PRESS RELEASE

published on 07/28/2025 at 13:00, 10 months 7 days ago

Moderna Announces Data to be Presented at ESMO Congress 2025
Moderna to present abstracts on investigational mRNA therapeutics at 2025 ESMO Congress. Mini oral presentation on mRNA-4359 and two poster presentations on intismeran autogene

Cancer Therapy MRNA Therapeutics Moderna ESMO Congress T-cell Immune Responses
BRIEF

published on 07/25/2025 at 14:50, 10 months 10 days ago

EMA Recommends Moderna's Updated COVID-19 Vaccine for EU Authorization

COVID-19 Vaccine European Commission Moderna EMA Approval SARS-CoV-2 LP.8.1
PRESS RELEASE

published on 07/25/2025 at 14:45, 10 months 10 days ago

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Moderna's updated COVID-19 mRNA vaccine targeting variant LP.8.1 receives positive CHMP opinion for EU marketing authorization. European Commission to decide for 2025-2026 season

COVID-19 Vaccine European Commission Moderna CHMP LP.8.1
BRIEF

published on 06/30/2025 at 13:05, 11 months 4 days ago

Moderna Reports Positive Phase 3 Results for Seasonal Influenza Vaccine

Moderna Influenza Vaccine Phase 3 Results RVE MRNA-1010

Accesswire

Published on 06/04/2026 at 14:45, 5 minutes ago

Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 2026
Published on 06/04/2026 at 14:30, 20 minutes ago

Predictiv AI's Shift Technologies Secures Multi-Phase Commercial Contract to Digitize and Scale Middle-Mile and Last-Mile Logistics for Prompt Xpress
Published on 06/04/2026 at 14:00, 50 minutes ago

Horizon Aircraft Appoints Richard Alexander as Chief Engineer of Certified Programs
Published on 06/04/2026 at 14:00, 50 minutes ago

GameSquare Issues Shareholder Letter Highlighting Strong Second Quarter and Year-to-Date Momentum
Published on 06/04/2026 at 14:00, 50 minutes ago

EQ Works Expands ClearLake Platform with AI-Powered Audience Segments

View all ACCESSWIRE

EQS Group

Published on 06/04/2026 at 14:35, 15 minutes ago

Eightco Holdings (NASDAQ: ORBS) Reports Total Holdings of Approximately $437 Million, Includes OpenAI, Beast Industries, More Than 16,000 ETH and Over 283 Million WLD Tokens
Published on 06/04/2026 at 14:09, 41 minutes ago

Diginex Expands Supply Chain End-to-End Product Suite Amid Accelerating Regulatory Pressure
Published on 06/04/2026 at 13:35, 1 hour 15 minutes ago

TCL Unveils Expanded Monitor Lineup in Europe, Including its First Flagship OLED+ Monitor
Published on 06/04/2026 at 13:15, 1 hour 35 minutes ago

Innovative Drug Update | Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10
Published on 06/04/2026 at 13:00, 1 hour 50 minutes ago

Haier Brings Youth Tennis and Fan Engagement to Roland-Garros 2026 with Clay Court Open and Fans Club Event

Les Echos

Published on 06/04/2026 at 07:50, 7 hours ago

Schneider Electric launches an offering of bonds convertible into new shares and/or exchangeable for existing shares (OCEANEs) due 2034 for a nominal amount of €800 million and a concurrent repurchase of its outstanding OCEANEs due 2030 by way of a re
Published on 06/03/2026 at 18:02, 20 hours 48 minutes ago

Information concerning the total number of voting rights and shares 2026 05 31
Published on 06/03/2026 at 17:45, 21 hours 5 minutes ago

Manitou Group signs an amendment to its Sustainability Linked Loan (SLL) credit agreement to align its ESG criteria with its LIFT strategy
Published on 06/03/2026 at 17:45, 21 hours 5 minutes ago

VOGO has won all lots in the National Rugby League’s latest call for tenders and has signed a strategic six-season partnership.
Published on 06/03/2026 at 17:45, 21 hours 5 minutes ago

Report on share repurchases from 27 May to 2 June 2026

View all LES ECHOS COMFI WIRE